Celgene backs next-gen oncolytic virus startup in $57M Series A

"Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of brain cancer, glioblastoma multiforme (GBM). Active strategic investor Celgene ($CELG) participated in the financing, which was led by MPM Capital."

Read the article from FierceBiotech